Preferred Label : atogepant;

UNII : 7CRV8RR151;

Details


Main resources

You can consult :


https://www.ema.europa.eu/en/medicines/human/EPAR/aquipta
2023
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
atogepant
atogepant
drug approval
europe
atogepant
administration, oral
adult
migraine disorders
product surveillance, postmarketing
aged
drug interactions
pregnancy
breast feeding
Calcitonin Gene-Related Peptide Receptor Antagonists
Calcitonin Gene-Related Peptide Receptor Antagonists
drug evaluation, preclinical

---
https://www.has-sante.fr/jcms/p_3483609/fr/aquipta-atogepant-migraine
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
atogepant
Refractory migraine (disorder)
administration, oral
evaluation of the transparency committee
atogepant
migraine disorders

---
https://www.cadth.ca/fr/atogepant
2022
false
false
false
Canada
French
atogepant
migraine disorders
drug information

---
Nous contacter.
18/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.